Behcet disease

【Product name】Cellcept

[English common name]Mycophenolate mofetil

[Chinese common name]Mycophenolate mofetil

[English name]

[Chinese other name]

[indications]
Mycophenolate mofetil for injection: This product is used as a preventive medication for organ rejection in patients receiving allogeneic kidney, heart or liver transplantation.
Mycophenolate capsules: prevention of rejection in the same kidney transplant patients and treatment of refractory rejection, can be applied simultaneously with cyclosporine and adrenocortical hormone.
Mycophenolate mofetil dry suspension: for the prevention of organ rejection in patients receiving allogeneic kidney or liver transplantation, mycophenolate mofetil should be combined with cyclosporin A or tacrolimus and corticosteroids Apply at the same time.
Mycophenolate tablets: autoimmune diseases such as pemphigus, bullous pemphigoid, systemic lupus erythematosus (SLE), psoriasis, and the like.
The mycophenolate dispersible tablet: the preventive rejection dose should be taken within 72 hours of transplantation. The recommended dose for kidney transplant patients is 1 gram twice a day (2 grams a day). For daily use, the mycophenolate dispersible tablet 2 g / day is safer than oral g / 3 g / day. Dosage for the Treatment of Refractory Rejection In clinical trials, the first and maintenance dose for the treatment of refractory rejection is recommended to be 1.5 g twice daily (3 g/day).

【Dosage】
Use of mycophenolate mofetil for injection: method of use and drug configuration: intravenous use of this product must be prepared with 5% glucose solution, two vials equivalent to 1 gram dose, the recommended concentration is 6 mg / ml, should use two-step dilution method .
1. The first step:
(1) Inject 20 ml of 5% glucose solution into each vial and shake well. Pay attention to aseptic operation.
(2) Gently shake the vial to dissolve the drug (if the room temperature is low, it can be slightly warm).
(3) After dissolution, the solution should be a pale yellow liquid with no impurities or precipitates. Otherwise it should be discarded.
2. The second step:
(1) The solution was further dissolved with 125 ml of a 5% glucose solution, and the final drug concentration was about 6 mg/ml.
(2) Observe whether the solution is transparent and free of impurities, otherwise it should be discarded.
Mycophenolate capsules: The dose to prevent rejection should be taken within 72 hours of transplantation. The recommended dose for kidney transplant patients is 1 gram twice a day (2 grams a day). Daily service for mycophenolate capsules 2 g / day is safer than oral 3 g / day. Dosage for the Treatment of Refractory Rejection In clinical trials, the first and maintenance dose for the treatment of refractory rejection is recommended to be 1.5 grams twice daily (3 g/day). Special doses should be stopped or reduced if neutropenia (absolute neutrophil count <1.3×103/μl) occurs. Severe renal dysfunction: For patients with severe chronic renal impairment (glomerular filtration rate <25 ml / min / 1.73 m2), avoid more than 1 gram, twice a day (except immediately after transplantation) .
Mycophenolate mofetil dry suspension:
1. The dose to prevent renal transplant rejection. The first dose of this product should be taken orally within 72 hours after transplantation. For kidney transplant patients, it is recommended to take 1 gram each time, twice a day (daily dose is 2 grams). Although 1.5 grams per day, twice a day (3 grams per day) was used in clinical trials and was safe and effective, it did not have an advantage in effect. Patients who received 2 grams of this product per day were better than the 3 grams of patients in terms of overall safety. This product should be applied at the same time as standard doses of cyclosporine and corticosteroids.
2. The dose of treatment for refractory renal transplant rejection. In clinical practice, the therapeutic and maintenance dose for refractory rejection is 1.5 grams each time, twice a day (daily dose is 3 grams). Therefore, a dose of 3 grams per day is recommended for clinical use.
Mycophenolate tablets: The dose of preventive rejection should be started orally within 72 hours of transplantation. The recommended dose for kidney transplant patients is 1 gram each time, twice a day (2 grams a day). Oral morphine mycophenolate tablets 2 g / day is better than oral 3 g / day overall safety. Dosage for the Treatment of Refractory Rejection In clinical trials, the first and maintenance doses for the treatment of refractory rejection are recommended to be 1.5 grams each time, twice a day (3 grams a day).
The mycophenolate dispersible tablet: the preventive rejection dose should be taken within 72 hours of transplantation. The recommended dose for kidney transplant patients is 1 gram twice a day (2 grams a day). For daily use, the mycophenolate dispersible tablet 2 g / day is safer than oral g / 3 g / day. Dosage for the Treatment of Refractory Rejection In clinical trials, the first and maintenance dose for the treatment of refractory rejection is recommended to be 1.5 g twice daily (3 g/day).

[Storage]
Mycophenolate mofetil for injection: sealed and stored.
Mycophenolate capsules: This product should be stored at 15-30 ° C, to avoid moisture, can not be taken after the expiration date indicated on the package. Drugs should be kept out of reach of children.
A dry suspension of mycophenolate mofetil: sealed, kept in a cool place.
Mycophenolate tablets: This product should be stored at 15-30 ° C in the dark. Do not take it after the expiration date indicated on the package. Keep the medicine out of reach of children.
Mycophenolate dispersible tablets: sealed and stored.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】Thalomid

[English common name]Thalidomide

[Chinese common name]Thalidomide

[English name]2-phthalimidoglutarimide

[Chinese other name]Thalidomide

[indications]
Thalidomide capsule: a dermatological treatment. Used to control neoplastic leprosy.
Thalidomide tablets: used to control neoplastic leprosy.

【Dosage】
Thalidomide capsules: 25-50mg (1-2 tablets) once a day, 100-200mg (4-8 tablets) a day or as directed by your doctor.
Thalidomide tablets: oral. 25-50mg (1-2 tablets), 100-200mg (4-8 tablets) a day, or as directed by your doctor.

[Storage]
Thalidomide capsules: shading, sealed storage.
Thalidomide tablets: shading, sealed and preserved.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】Prosperous, Methotrexat, RHEUMATREX

[English common name]Methotrexate

[Chinese common name]Methotrexate

[English name]

[Chinese other name]

[indications]
Methotrexate injection:
Methotrexate has broad-spectrum anti-tumor activity and can be used alone or in combination with other chemotherapeutic drugs. The specific indications are as follows:
1. Anti-tumor treatment alone:Breast cancer, gestational choriocarcinoma,Malignant moleOr a mole.
2. Anti-tumor therapy combined use:Acute leukemia(especially acuteLymphocytic leukemia), Burkitts lymphoma, advanced lymphosarcoma (stages III and IV, according to Peter staging) and advanced mycosis fungoides.
3. Intrathecal injection: treatment of meningeal metastases (only isotonic preparations can be used).
4. High-dose treatment: high-dose methotrexate alone or in combination with other chemotherapeutic drugs for the following tumors: osteosarcoma, acute leukemia, bronchusLung cancerOr head and neck epidermal cancer.
Methotrexate tablets:
1. All types of acute leukemia, especially large granular lymphocytic leukemia,Malignant lymphoma, non-Hodgkin's lymphoma and mycosis fungoides,Multiple myelopathy.
2. Head and neck cancer, lung cancer, various soft tissue sarcomas, pediatric soft tissue sarcoma, psoriasis.
3. Breast cancer, ovarian cancer, cervical cancer, malignant mole, chorionic epithelial cancer, testicular cancer, saddle-top germ cell tumor.

【Dosage】
Methotrexate injection:
1. Recommended dose: It is recommended to take sorafenib for 0.4 g (2 × 0.2 g) each time, twice daily, on an empty stomach or with a low-fat, medium-fat diet.
2. How to take it: Oral, swallow it with a cup of warm water.
Methotrexate tablets:
1. Oral, adult 5 ~ 10mg once a day, 1 or 2 times a week, a safe dose of 50 ~ 100mg.
2. For the maintenance treatment of acute lymphocytic leukemia, once 15 ~ 20mg / m2, once a week.

[Storage]
Methotrexate injection: Store at 25 ° C or less in the dark. Each bottle is for one use only, and the excess is discarded.
Methotrexate tablets: shading, sealed and preserved.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】REMICADE, Remicade

[English common name]Infliximab

[Chinese common name]Infliximab

[English name]

[Chinese other name]

[indications]
Rheumatoid Arthritis
This product is a disease-control anti-rheumatic drug. For patients with moderate to severe active rheumatoid arthritis, this product can be used in combination with methotrexate:
· Reduce symptoms and signs;
· Improve physical function and prevent disability in patients.
Crohn's disease
For patients with moderate to severe active Crohn's disease who are not well received by traditional treatment, this product can be used for:
· Reduce symptoms and signs;
· Achieve and maintain clinical efficacy;
· Promote mucosal healing;
· Improve the quality of life;
· Reduce the amount of corticosteroids or stop using corticosteroids.
Tracheal Crohn's disease
For patients with fistile Crohn's disease, this product can be used for:
Reduce the number of intestinal-cutaneous fistulas and rectal-vaginal fistulas to promote and maintain fistula healing;
· Reduce symptoms and signs;
· Improve the quality of life.
Ankylosing spondylitis
For patients with active ankylosing spondylitis, this product can be used for:
· Alleviate symptoms and signs, including increasing the range of activity;
· Improve physical function;
· Improve the quality of life.
psoriasis
For patients with psoriasis, this product can be used for:
Adult patients with chronic severe plaque psoriasis who require systemic treatment and are ineffective, contraindicated or tolerant to other systems such as cyclosporine, methotrexate or photochemotherapy. This product is intended for use only in patients who are treated under close supervision by a physician and regularly followed up by a physician.

【Dosage】
Usage: intravenous infusion.
Rheumatoid Arthritis
The product was administered 3 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. This product should be combined with methotrexate. For patients with poor efficacy, consider adjusting the dose to 10 mg/kg and/or adjusting the medication interval to 4 weeks.
Moderate and severe active Crohn's disease, fistula Crohn's disease
The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. For patients with poor efficacy, consider adjusting the dose to 10 mg/kg.
Ankylosing spondylitis
The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 6 weeks after the second week and the sixth week after the first administration and thereafter.
User guides
Sterility should be performed.
1. Calculate the dosage and determine the number of bottles used in this product: This product contains 100mg of infliximab per bottle, and calculate the total amount of the solution to be prepared.
2. Dissolve each bottle of medicine with 10 ml of sterile water for injection using a syringe equipped with a 21 gauge (0.8 mm) or smaller needle: remove the flip of the vial, wipe the top of the vial with a medical alcohol swab, and insert the syringe needle into the vial Cover, inject sterile water for injection. If the vacuum in the vial has been destroyed, the bottle cannot be used. Gently rotate the vial to dissolve the powder. Avoid shaking for a long time or with force. Do not oscillate. Foam may appear during the dissolution of the drug. After 5 minutes of storage, the solution should be colorless or light yellow, and the milk is white. Since infliximab is a protein, there may be some translucent particles in the solution. If opaque particles, discoloration or other substances appear in the solution, they cannot be used any more.
3. Dilute the sterile aqueous solution of this product to 250 ml with 0.9% sodium chloride injection: withdraw the same amount of liquid from the 250 ml 0.9% sodium chloride injection bottle or bag as the sterile injectable aqueous solution of this product. The sterile aqueous solution for injection of this product is completely injected into the infusion bottle or bag and gently mixed.
4. The infusion time should not be less than 2 hours: the infusion set should be equipped with a built-in, sterile, pyrogen-free, low protein binding filter (pore size ≤ 1.2 μm). Unused infusions should not be stored for further use.
5. The physical and biochemical compatibility studies of this product in combination with other drugs have not been carried out, and this product should not be infused simultaneously with other drugs.
Products administered parenterally should be visually inspected for the presence of particulate matter or discoloration prior to administration. If opaque particles, discoloration, or other foreign matter are found, the drug may not be used.
Plaque psoriasis
The product was administered 5 mg/kg for the first time, and then the same dose was administered once every 8 weeks after the second week and the sixth week after the first administration and thereafter. If the patient does not respond after week 14 (ie, after 4 doses), the product should not be treated.
Psoriasis patients re-administered
Patients with psoriasis have limited experience with a single administration after 20 weeks, suggesting a reduction in the effectiveness of the product compared to the initial induction therapy and an increase in mild to moderate infusion response.
After relapse of the disease, limited experience with repeated induction therapy showed an increase in infusion response (including severe reactions) compared to 8-week maintenance therapy.
If treatment interruption is maintained, it is not recommended to initiate induction therapy again and should be re-administered according to maintenance therapy.

[Storage]Store at 2-8 °C in the dark.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.